Abstract
Inactivating tolC in multidrug-resistant Escherichia coli with differing sequence types and quinolone resistance-determining mutations reveals remarkably potentiated activity of the first-in-class topoisomerase inhibitors gepotidacin and zoliflodacin. Differences between both structurally unrelated compounds in comparison to fluoroquinolones regarding the selectivity of E. coli RND (resistance-nodulation-cell division)-type transporters, efflux inhibitors, and AcrB porter domain mutations were demonstrated.
Funding Information
  • Innovative Medicines Initiative (IMI) Joint Undertaking European Union Seventh Framework Program and EFPIA Companies (115525 ND4BB Translocation)

This publication has 25 references indexed in Scilit: